0001209191-20-050504.txt : 20200915 0001209191-20-050504.hdr.sgml : 20200915 20200915171102 ACCESSION NUMBER: 0001209191-20-050504 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200915 FILED AS OF DATE: 20200915 DATE AS OF CHANGE: 20200915 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nashat Amir CENTRAL INDEX KEY: 0001575843 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39512 FILM NUMBER: 201176680 MAIL ADDRESS: STREET 1: 10835 ROAD TO THE CURE STREET 2: SUITE 205 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Metacrine, Inc. CENTRAL INDEX KEY: 0001634379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472297384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-369-7800 MAIL ADDRESS: STREET 1: 3985 SORRENTO VALLEY BLVD., SUITE C CITY: SAN DIEGO STATE: CA ZIP: 92121 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-09-15 0 0001634379 Metacrine, Inc. MTCR 0001575843 Nashat Amir C/O METACRINE, INC. 3985 SORRENTO VALLEY BLVD., SUITE C SAN DIEGO CA 92121 1 0 1 0 Series A Convertible Preferred Stock Common Stock 1832582 I See footnote Series A Convertible Preferred Stock Common Stock 128201 I See footnote Series B Convertible Preferred Stock Common Stock 451666 I See footnote Series B Convertible Preferred Stock Common Stock 20585 I See footnote Series C Convertible Preferred Stock Common Stock 216106 I See footnote Series C Convertible Preferred Stock Common Stock 15118 I See footnote Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") are convertible into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock has no expiration date. The reportable securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of the Reporting Person, a member of the Issuer's Board of Directors, David Barrett ("Barrett"), Brian Chee ("Chee") and Bryce Youngren ("Youngren" and, together with the Reporting Person, Barrett and Chee, the "Managing Members") are the managing members of PMC VII. (continued from Footnote 2) Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PP VII. Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. The reportable securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of the Managing Members, in their respective capacities with respect to PMC VII, may be deemed to have shared voting and dispositive power over the shares held by PEF VII. (continued from Footnote 4) Each of PMC VII and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. /s/ Lauren Crockett, Attorney-in-fact for Amir Nashat 2020-09-15